person · Reporting owner

Silverman Peter B.

Disclosed activity across 3 companies

Tapewire entity: 27987
SEC CIK: 0001790314

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
LeonaBio, Inc.LONA · Entity 1487	Director	June 23, 2026	June 24, 2026
Yarrow Bioscience, Inc.YARW · Entity 6871	Director	July 27, 2026	July 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

LeonaBio, Inc.

Report date June 23, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.35 · Expires 2036-06-22	Direct	2,333	Reported balance After 2026-06-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-23 · Grant · Acquired 2,333 · Balance 2,333 F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026.

Yarrow Bioscience, Inc.

Report date July 27, 2026 · Filed July 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.19 · Expires 2036-04-17	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-07-27 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer"). F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time. F3: This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").

F2: Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.

F3: This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Merus N.V.

Report date December 12, 2025 · Filed December 12, 2025

Section 16 reporting ended · disclosed 2025-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.43 · Expires 2031-02-16	Direct	Reported balance After 2025-12-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-12-12 · Disposition to issuer · Disposed 50,000 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.65 · Expires 2035-01-29	Direct	Reported balance After 2025-12-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-12 · Disposition to issuer · Disposed 125,000 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.09 · Expires 2034-01-31	Direct	Reported balance After 2025-12-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-12 · Disposition to issuer · Disposed 107,300 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2029-02-20	Direct	Reported balance After 2025-12-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-12 · Disposition to issuer · Disposed 3,900 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.37 · Expires 2030-04-16	Direct	Reported balance After 2025-12-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-12-12 · Disposition to issuer · Disposed 12,714 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.07 · Expires 2033-02-02	Direct	Reported balance After 2025-12-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-12-12 · Disposition to issuer · Disposed 104,000 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.87 · Expires 2033-01-01	Direct	Reported balance After 2025-12-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-12-12 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.61 · Expires 2032-01-31	Direct	Reported balance After 2025-12-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-12-12 · Disposition to issuer · Disposed 83,000 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Filing footnotes · ownership attribution and instrument terms

F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 23, 2026 Filed Jun 24, 2026 22:33 UTC	LeonaBio, Inc. LONA · Entity 1487	GrantStock Option (Right to Buy) · Derivative	2,333	$0.00 Strike: $8.35	$0.00	Disclosure SEC source: 0001790314-26-000004 · form4-06242026_100642.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,333 Underlying: Common Stock · 2,333 shares Expires 2036-06-22 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy and is pro-rated based on the reporting person's appointment to the Issuer's board of directors on May 5, 2026. Read SEC document
May 05, 2026 Filed May 8, 2026 00:26 UTC	LeonaBio, Inc. LONA · Entity 1487	GrantStock Option (Right to Buy) · Derivative	56,000	$0.00 Strike: $9.63	$0.00	Disclosure SEC source: 0001790314-26-000003 · form4-05082026_120552.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2036-05-04 F1 · derivative.exercise_date: The shares subject to the option are scheduled to vest monthly over a term of 36 months on the monthly anniversaries of the grant date, subject to the optionee continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through the applicable vesting dates. Read SEC document
December 12, 2025 Filed Dec 12, 2025 19:02 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	83,000	$0.00 Strike: $24.61	$0.00	Disclosure SEC source: 0001193125-25-317957 · ownership.xml · derivative · entry 8 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 83,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 19:02 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	20,000	$0.00 Strike: $15.87	$0.00	Disclosure SEC source: 0001193125-25-317957 · ownership.xml · derivative · entry 7 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 19:02 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	104,000	$0.00 Strike: $16.07	$0.00	Disclosure SEC source: 0001193125-25-317957 · ownership.xml · derivative · entry 6 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 104,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 19:02 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	12,714	$0.00 Strike: $12.37	$0.00	Disclosure SEC source: 0001193125-25-317957 · ownership.xml · derivative · entry 5 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 12,714 shares Expires 2030-04-16 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 19:02 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	3,900	$0.00 Strike: $11.16	$0.00	Disclosure SEC source: 0001193125-25-317957 · ownership.xml · derivative · entry 4 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,900 shares Expires 2029-02-20 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 19:02 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	107,300	$0.00 Strike: $36.09	$0.00	Disclosure SEC source: 0001193125-25-317957 · ownership.xml · derivative · entry 3 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 107,300 shares Expires 2034-01-31 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 19:02 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	125,000	$0.00 Strike: $41.65	$0.00	Disclosure SEC source: 0001193125-25-317957 · ownership.xml · derivative · entry 2 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 125,000 shares Expires 2035-01-29 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
December 12, 2025 Filed Dec 12, 2025 19:02 UTC	Merus N.V. MRUS · Entity 70740	Disposition to issuerShare Option (right to buy) · Derivative	50,000	$0.00 Strike: $24.43	$0.00	Disclosure SEC source: 0001193125-25-317957 · ownership.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 50,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time. F2 · derivative.exercise_date: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option. Read SEC document
July 17, 2025 Filed Jul 18, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	25,000	$0.00 Strike: $24.43	$0.00	Disclosure SEC source: 0000950170-25-096919 · ownership.xml · derivative · entry 3 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 25,000 shares Expires 2031-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F4 · derivative.exercise_date: The options are fully vested and exercisable. F5 · balance_after: Number of derivative securities beneficially owned following the reported transaction is in reference to the number of options that remain outstanding of those originally granted on February 16, 2021. Read SEC document
July 17, 2025 Filed Jul 18, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	SaleCommon Shares	25,000	$60.00	$1,500,000.00	Disclosure SEC source: 0000950170-25-096919 · ownership.xml · nonDerivative · entry 2 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F3 · price: Amount represents the weighted average price of shares sold, which ranged from $60.00 to $60.07. Details of individual transactions are available upon request. Read SEC document
July 17, 2025 Filed Jul 18, 2025 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	25,000	$24.43	$610,750.00	Disclosure SEC source: 0000950170-25-096919 · ownership.xml · nonDerivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F2 · price: Represents the exercise price of the options originally granted on February 16, 2021. Read SEC document
July 10, 2025 Filed Jul 11, 2025 16:09 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	16,805	$0.00 Strike: $18.61	$0.00	Disclosure SEC source: 0000950170-25-095292 · ownership.xml · derivative · entry 6 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 16,805 shares Expires 2030-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F5 · derivative.exercise_date: The options are fully vested and exercisable. F6 · balance_after: Number of derivative securities beneficially owned following the reported transaction is in reference to the number of options that remain outstanding of those originally granted on February 14, 2020. Read SEC document
July 10, 2025 Filed Jul 11, 2025 16:09 UTC	Merus N.V. MRUS · Entity 70740	SaleCommon Shares	16,805	$55.00	$924,275.00	Disclosure SEC source: 0000950170-25-095292 · ownership.xml · nonDerivative · entry 4 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F4 · price: Amount represents the weighted average price of shares sold, which ranged from $55.00 to $55.04. Details of individual transactions are available upon request. Read SEC document
July 10, 2025 Filed Jul 11, 2025 16:09 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	16,805	$18.61	$312,741.05	Disclosure SEC source: 0000950170-25-095292 · ownership.xml · nonDerivative · entry 3 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F2 · price: Represents the exercise price of the options originally granted on February 14, 2020. Read SEC document
July 09, 2025 Filed Jul 11, 2025 16:09 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	6,695	$0.00 Strike: $18.61	$0.00	Disclosure SEC source: 0000950170-25-095292 · ownership.xml · derivative · entry 5 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,805 Underlying: Common Shares · 6,695 shares Expires 2030-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F5 · derivative.exercise_date: The options are fully vested and exercisable. F6 · balance_after: Number of derivative securities beneficially owned following the reported transaction is in reference to the number of options that remain outstanding of those originally granted on February 14, 2020. Read SEC document
July 09, 2025 Filed Jul 11, 2025 16:09 UTC	Merus N.V. MRUS · Entity 70740	SaleCommon Shares	6,695	$55.00	$368,225.00	Disclosure SEC source: 0000950170-25-095292 · ownership.xml · nonDerivative · entry 2 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F3 · price: Amount represents the weighted average price of shares sold, which ranged from $55.00 to $55.07. Details of individual transactions are available upon request. Read SEC document
July 09, 2025 Filed Jul 11, 2025 16:09 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	6,695	$18.61	$124,593.95	Disclosure SEC source: 0000950170-25-095292 · ownership.xml · nonDerivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F2 · price: Represents the exercise price of the options originally granted on February 14, 2020. Read SEC document
June 20, 2025 Filed Jun 24, 2025 16:00 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	34,000	$0.00 Strike: $18.61	$0.00	Disclosure SEC source: 0000950170-25-089442 · ownership.xml · derivative · entry 3 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Shares · 34,000 shares Expires 2030-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F4 · derivative.exercise_date: The options are fully vested and exercisable. F5 · balance_after: Number of derivative securities beneficially owned following the reported transaction is in reference to the number of options that remain outstanding of those originally granted on February 14, 2020. Read SEC document
June 20, 2025 Filed Jun 24, 2025 16:00 UTC	Merus N.V. MRUS · Entity 70740	SaleCommon Shares	34,000	$52.76	$1,793,840.00	Disclosure SEC source: 0000950170-25-089442 · ownership.xml · nonDerivative · entry 2 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F3 · price: Amount represents the weighted average price of shares sold, which ranged from $52.44 to $53.06. Details of individual transactions are available upon request. Read SEC document
June 20, 2025 Filed Jun 24, 2025 16:00 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	34,000	$18.61	$632,740.00	Disclosure SEC source: 0000950170-25-089442 · ownership.xml · nonDerivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 20, 2025. F2 · price: Represents the exercise price of the options originally granted on February 14, 2020. Read SEC document
January 29, 2025 Filed Jan 31, 2025 16:32 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	125,000	$0.00 Strike: $41.65	$0.00	Disclosure SEC source: 0000950170-25-011798 · ownership.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2035-01-29 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2025. 25% vest on January 1, 2026 and in 36 equal monthly installments thereafter. Read SEC document
June 27, 2024 Filed Jun 28, 2024 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	7,453	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0000950170-24-079035 · ownership.xml · derivative · entry 5 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 7,453 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. F2 · derivative.exercise_date: The options is fully vested and exercisable. Read SEC document
June 27, 2024 Filed Jun 28, 2024 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	2,547	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0000950170-24-079035 · ownership.xml · derivative · entry 4 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 2,547 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. F2 · derivative.exercise_date: The options is fully vested and exercisable. Read SEC document
June 27, 2024 Filed Jun 28, 2024 16:05 UTC	Merus N.V. MRUS · Entity 70740	SaleCommon Shares	10,000	$60.00	$600,000.00	Disclosure SEC source: 0000950170-24-079035 · ownership.xml · nonDerivative · entry 3 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. Read SEC document
June 27, 2024 Filed Jun 28, 2024 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	7,453	$17.94	$133,706.82	Disclosure SEC source: 0000950170-24-079035 · ownership.xml · nonDerivative · entry 2 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. Read SEC document
June 27, 2024 Filed Jun 28, 2024 16:05 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	2,547	$17.94	$45,693.18	Disclosure SEC source: 0000950170-24-079035 · ownership.xml · nonDerivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	9,253	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · derivative · entry 9 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,453 Underlying: Common Shares · 9,253 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	2,747	$0.00 Strike: $17.94	$0.00	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · derivative · entry 8 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,547 Underlying: Common Shares · 2,747 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	41,577	$0.00 Strike: $25.90	$0.00	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · derivative · entry 7 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 41,577 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	8,423	$0.00 Strike: $25.90	$0.00	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · derivative · entry 6 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,423 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	SaleCommon Shares	62,000	$56.52	$3,504,178.00	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · nonDerivative · entry 5 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	9,253	$17.94	$165,998.82	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · nonDerivative · entry 4 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	2,747	$17.94	$49,281.18	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · nonDerivative · entry 3 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	41,577	$25.90	$1,076,844.30	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · nonDerivative · entry 2 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. Read SEC document
June 17, 2024 Filed Jun 20, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	8,423	$25.90	$218,155.70	Disclosure SEC source: 0000950170-24-075625 · ownership.xml · nonDerivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 15, 2024. Read SEC document
May 07, 2024 Filed May 9, 2024 16:30 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	107,300	$0.00 Strike: $36.09	$0.00	Disclosure SEC source: 0000950170-24-057089 · ownership.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,300 Underlying: Common Shares · 107,300 shares Expires 2034-01-31 F1 · date: On February 1, 2024, the Board of Directors approved the grant of options to purchase the common shares, at an exercise price of $36.09 per share, subject to the Company's general meeting resolving upon, and the Board having implemented through an amendment to the Company's articles of association, an increase in the authorized share capital sufficient to satisfy the award set forth (the "Shareholder Approval Condition"). On May 7, 2024, the shareholders approved the amendment to the Company's articles of association, including the increase in the authorized share capital satisfying the Shareholder Approval Condition. F2 · derivative.exercise_date: Options vest over a four-year period from January 1, 2024. 25% vest on January 1, 2025 and in 36 equal monthly installments thereafter. Read SEC document
December 15, 2023 Filed Dec 18, 2023 17:15 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	1,286	$0.00 Strike: $12.37	$0.00	Disclosure SEC source: 0001209191-23-058994 · doc4.xml · derivative · entry 5 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,286 shares Expires 2030-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents the exercise price of the options originally granted on April 16, 2020. F6 · derivative.exercise_date: Options vest over a four-year period commencing April 16, 2020. 25% vest after one year and in 36 equal monthly installments thereafter. F7 · balance_after: Number of derivative securities beneficially owned following the reported transaction is in reference to the number of options that remain outstanding of those originally granted on April 20, 2020. Read SEC document
December 15, 2023 Filed Dec 18, 2023 17:15 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	21,100	$0.00 Strike: $11.16	$0.00	Disclosure SEC source: 0001209191-23-058994 · doc4.xml · derivative · entry 4 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 21,100 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the exercise price of the options originally granted on February 20, 2019. F4 · derivative.exercise_date: Options vest over a four-year period commencing February 20, 2019. 25% vest after one year and in 36 equal monthly installments thereafter. F5 · balance_after: Number of derivative securities beneficially owned following the reported transaction is in reference to the number of options that remain outstanding of those originally granted on February 20, 2019. Read SEC document
December 15, 2023 Filed Dec 18, 2023 17:15 UTC	Merus N.V. MRUS · Entity 70740	SaleCommon Shares	22,386	$25.00	$559,650.00	Disclosure SEC source: 0001209191-23-058994 · doc4.xml · nonDerivative · entry 3 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Amount represents the weighted average price of shares sold, which ranged from $25.02 to $25.00. Details of individual transactions are available upon request. Read SEC document
December 15, 2023 Filed Dec 18, 2023 17:15 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	1,286	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-058994 · doc4.xml · nonDerivative · entry 2 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Represents the exercise price of the options originally granted on April 16, 2020. Read SEC document
December 15, 2023 Filed Dec 18, 2023 17:15 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	21,100	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-058994 · doc4.xml · nonDerivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the exercise price of the options originally granted on February 20, 2019. Read SEC document
February 02, 2023 Filed Feb 3, 2023 16:25 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	104,000	$0.00 Strike: $16.07	$0.00	Disclosure SEC source: 0001209191-23-006853 · doc4.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Shares · 104,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2023. 25% vest on January 1, 2024 and in 36 equal monthly installments thereafter. Read SEC document
January 04, 2023 Filed Jan 6, 2023 08:54 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option(right to buy) · Derivative	20,000	$0.00 Strike: $15.87	$0.00	Disclosure SEC source: 0001209191-23-002234 · doc4.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · COO & GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2033-01-01 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2023. 25% vest on January 1, 2024 and in 36 equal installments thereafter. Read SEC document
March 10, 2022 Filed Mar 11, 2022 14:34 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	60,000	$0.00 Strike: $11.16	$0.00	Disclosure SEC source: 0001209191-22-018129 · doc4.xml · derivative · entry 3 Silverman Peter B. · CIK 0001790314 · EVP, GC and Head of Utrecht 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,100 Underlying: Common Shares · 60,000 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the exercise price of the options originally granted on February 20, 2019. F3 · derivative.exercise_date: Options vest over a four-year period commencing February 20, 2019. 25% vest after one year and in 36 equal monthly installments thereafter. F4 · balance_after: Number of derivative securities beneficially owned following the reported transaction is in reference to the number of options that remain outstanding of those originally granted on February 20, 2019. Read SEC document
March 10, 2022 Filed Mar 11, 2022 14:34 UTC	Merus N.V. MRUS · Entity 70740	SaleCommon Shares	60,000	$26.95	$1,617,000.00	Disclosure SEC source: 0001209191-22-018129 · doc4.xml · nonDerivative · entry 2 Silverman Peter B. · CIK 0001790314 · EVP, GC and Head of Utrecht 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Amount represents the weighted average price of shares sold, which ranged from $26.50 to $27.36. Details of individual transactions are available upon request. Read SEC document
March 10, 2022 Filed Mar 11, 2022 14:34 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	60,000	$11.16	$669,600.00	Disclosure SEC source: 0001209191-22-018129 · doc4.xml · nonDerivative · entry 1 Silverman Peter B. · CIK 0001790314 · EVP, GC and Head of Utrecht 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the exercise price of the options originally granted on February 20, 2019. Read SEC document
January 31, 2022 Filed Feb 2, 2022 13:59 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	83,000	$0.00 Strike: $24.61	$0.00	Disclosure SEC source: 0001209191-22-006287 · doc4.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · EVP, GC and Head of Utrecht 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Shares · 83,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2022. 25% vest on January 1, 2023 and in 36 equal monthly installments thereafter. Read SEC document
February 16, 2021 Filed Feb 18, 2021 16:00 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	75,000	$0.00 Strike: $24.43	$0.00	Disclosure SEC source: 0001209191-21-011781 · doc4.xml · derivative · entry 1 Silverman Peter B. · CIK 0001790314 · EVP, GC and Head of Utrecht 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: Options vest over a four-year period from January 1, 2021. 25% vest on January 1, 2022 and in 36 equal monthly installments thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.